Patients with 1 AE were 66.6 % with rilonacept versus 59.1 % placebo , with slightly more AE-related withdrawals with rilonacept ( 4.7 % vs 3.0 % ) because of the greater incidence of injection site reactions ( 15.2 % rilonacept , 3.3 % placebo ) .